Replimune Group, Inc.

Replimune Group, Inc. is a clinical-stage biotechnology company dedicated to pioneering the next generation of oncolytic immunotherapies for the treatment of cancer. The company's innovative approach leverages proprietary oncolytic viruses engineered to selectively infect and destroy cancer cells while simultaneously stimulating a potent anti-tumor immune response. This dual mechanism of action aims to overcome the limitations of current cancer therapies by activating the patient's own immune system to recognize and eliminate malignant cells. Replimune's lead product candidate, RP1, is an engineered herpes simplex virus type 1 (HSV-1) designed to express granulocyte-macrophage colony-stimulating factor (GM-CSF) and a modified viral entry mechanism, targeting a broad spectrum of solid tumors. Further advancing its pipeline, the company is developing RP2, which incorporates an anti-CTLA-4 antibody-like protein to enhance immune activation by blocking immune checkpoints, and RP3, designed to express other immune-stimulating proteins to further bolster T cell responses. By focusing on these advanced oncolytic immunotherapy platforms, Replimune is strategically positioned to address significant unmet needs in oncology, aiming to transform the treatment landscape for patients with difficult-to-treat cancers.